Sanofi-Aventis Avalide Product Recall(2021-06-14)
· Published by Health Canada · Official notice
Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type I
A. Avalide 300-12.5 mg
| Lot or serial number | Companies | Brand name | DIN, NPN, DIN-HIM | Dosage form | Strength |
|---|
| ET02879, FT01327 | - Recalling Firm
- Sanofi-Aventis Canada Inc.
- 2905 Place Louis.R-Renaud
- Laval
- H7V 0A3
- Quebec
- CANADA
- Marketing Authorization Holder
- Sanofi-Aventis Canada Inc.
- 2905 Place Louis.R-Renaud
- Laval
- H7V 0A3
- Quebec
- CANADA
| B. Avalide 150-12.5 mg | DIN 02241818 | Tablet | Irbesartan 150 mg |
| FT01644 | - Recalling Firm
- Sanofi-Aventis Canada Inc.
- 2905 Place Louis.R-Renaud
- Laval
- H7V 0A3
- Quebec
- CANADA
- Marketing Authorization Holder
- Sanofi-Aventis Canada Inc.
- 2905 Place Louis.R-Renaud
- Laval
- H7V 0A3
- Quebec
- CANADA
| A. Avalide 300-12.5 mg | DIN 02241819 | Tablet | Irbesartan 300 mg |
Presence of impurity 5-(4-(azidomethyl)-[1,1-biphenyl]-2-yl)-1H-tetrazole above the acceptable concentration
limit in affected lot.
Retailers, Other (healthcare practioners)